N
Ningyan Zhang
Researcher at University of Texas Health Science Center at Houston
Publications - 48
Citations - 2774
Ningyan Zhang is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 18, co-authored 48 publications receiving 2055 citations. Previous affiliations of Ningyan Zhang include Schering-Plough & Merck & Co..
Papers
More filters
Journal ArticleDOI
TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Yingjun Zhao,Xi-Lin Wu,Xiaoguang Li,Lu Lin Jiang,Xun Gui,Yan Liu,Yu Sun,Bing Zhu,Juan C. Piña-Crespo,Muxian Zhang,Ningyan Zhang,Xiaochun Chen,Guojun Bu,Zhiqiang An,Timothy Y. Huang,Huaxi Xu,Huaxi Xu +16 more
TL;DR: TREM2 is demonstrated as a microglial Aβ receptor transducing physiological and AD-related pathological effects associated with Aβ, and TREM2 interaction with its signaling adaptor DAP12 is enhanced by A β, regulating downstream phosphorylation of SYK and GSK3β.
Journal ArticleDOI
Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction
Kai Sun,Jiyoung Park,Olga T. Gupta,William L. Holland,Pernille Auerbach,Ningyan Zhang,Roberta Goncalves Marangoni,Sarah M. Nicoloro,Michael P. Czech,John Varga,Thorkil Ploug,Zhiqiang An,Philipp E. Scherer +12 more
TL;DR: It is demonstrated that endotrophin plays a pivotal role in shaping a metabolically unfavourable microenvironment in adipose tissue during consumption of a high-fat diet (HFD) and is established as a potential target in the context of metabolism and cancer.
Journal ArticleDOI
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Miguel Aste-Amezaga,Ningyan Zhang,Janet Lineberger,Beth A. Arnold,Timothy J. Toner,Mingcheng Gu,Lingyi Huang,Salvatore Vitelli,Kim Vo,Peter Haytko,Jing Zhang Zhao,Frederic Baleydier,Sarah L'Heureux,Hongfang Wang,Wendy R. Gordon,Elizabeth Thoryk,Marie Blanke Andrawes,Kittichoat Tiyanont,Kimberly Stegmaier,Kimberly Stegmaier,Giovanni Roti,Kenneth N. Ross,Laura L. Franlin,Hui Wang,Fubao Wang,Michael Chastain,Andrew J. Bett,Laurent P. Audoly,Jon C. Aster,Stephen C. Blacklow,Hans E. Huber +30 more
TL;DR: In vitro activities of inhibitory Notch1 monoclonal antibodies derived from cell-based and solid-phase screening of a phage display library may have clinical utility for conditions in which inhibition of signaling by wild-type notch1 is desired, but are likely to be of limited value for treatment of T-ALLs associated with aberrant Notch 1 activation.
Journal ArticleDOI
Improving tolerance of Candida antarctica lipase B towards irreversible thermal inactivation through directed evolution
TL;DR: Direct evolution is used to create CALB mutants with improved resistance towards irreversible thermal inactivation and over a 20-fold increase in half-life at 70 degrees C compared with the wild-type CALB (WT-CALB).
Journal ArticleDOI
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Yun Shi,Xuejun Fan,Hui Deng,Randall J. Brezski,Michael A. Rycyzyn,Robert Jordan,William R. Strohl,Quanming Zou,Ningyan Zhang,Zhiqiang An +9 more
TL;DR: Results indicated that activation of macrophages in combination with trastuzumab can serve as a therapeutic strategy for treating high HER2 breast cancer by boosting ADCP killing of cancer cells.